Sofie M A Walenbergh1, Tom Houben1, Tim Hendrikx1, Mike L J Jeurissen1, Patrick J van Gorp1, Anita C E Vreugdenhil2, Marlou P Adriaanse2, Wim A Buurman3, Marten H Hofker4, Antonella Mosca5, Patrick J Lindsey6, Anna Alisi5, Daniela Liccardo7, Nadia Panera8, Ger H Koek9, Valerio Nobili5, Ronit Shiri-Sverdlov1. 1. Department of Molecular Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands. 2. Department of Paediatrics and Nutrition, Maastricht University Medical Centre, Maastricht, The Netherlands. 3. Department of Surgery and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, The Netherlands. 4. Department of Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. 1] Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, Rome, Italy [2] Liver Research Unit, "Bambino Gesù" Children's Hospital, IRCCS, Rome, Italy. 6. Department of Population Genetics, Maastricht University, Maastricht, The Netherlands. 7. Hepato-Metabolic Disease Unit, "Bambino Gesù" Children's Hospital, IRCCS, Rome, Italy. 8. Liver Research Unit, "Bambino Gesù" Children's Hospital, IRCCS, Rome, Italy. 9. Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Abstract
OBJECTIVES: Nonalcoholic steatohepatitis (NASH) is the most severe form of a hepatic condition known as nonalcoholic fatty liver disease (NAFLD). NASH is histologically characterized by hepatic fat accumulation, inflammation, and ballooning, and eventually coupled with fibrosis that, in turn, may progress to end-stage liver disease even in young individuals. Hence, there is a critical need for specific noninvasive markers to predict hepatic inflammation at an early age. We investigated whether plasma levels of cathepsin D (CatD), a lysosomal protease, correlated with the severity of liver inflammation in pediatric NAFLD. METHODS: Liver biopsies from children (n=96) with NAFLD were histologically evaluated according to the criteria of Kleiner (NAFLD activity score) and the Brunt's criteria. At the time of liver biopsy, blood was taken and levels of CatD, alanine aminotransferase (ALT), and cytokeratin-18 (CK-18) were measured in plasma. RESULTS: Plasma CatD levels were significantly lower in subjects with liver inflammation compared with steatotic subjects. Furthermore, we found that CatD levels were gradually reduced and corresponded with increasing severity of liver inflammation, steatosis, hepatocellular ballooning, and NAFLD activity score. CatD levels correlated with pediatric NAFLD disease progression better than ALT and CK-18. In particular, CatD showed a high diagnostic accuracy (area under receiver operating characteristic curve (ROC-AUC): 0.94) for the differentiation between steatosis and hepatic inflammation, and reached almost the maximum accuracy (ROC-AUC: 0.998) upon the addition of CK-18. CONCLUSIONS: Plasma CatD holds a high diagnostic value to distinguish pediatric patients with hepatic inflammation from children with steatosis.
OBJECTIVES:Nonalcoholic steatohepatitis (NASH) is the most severe form of a hepatic condition known as nonalcoholic fatty liver disease (NAFLD). NASH is histologically characterized by hepatic fat accumulation, inflammation, and ballooning, and eventually coupled with fibrosis that, in turn, may progress to end-stage liver disease even in young individuals. Hence, there is a critical need for specific noninvasive markers to predict hepatic inflammation at an early age. We investigated whether plasma levels of cathepsin D (CatD), a lysosomal protease, correlated with the severity of liver inflammation in pediatric NAFLD. METHODS: Liver biopsies from children (n=96) with NAFLD were histologically evaluated according to the criteria of Kleiner (NAFLD activity score) and the Brunt's criteria. At the time of liver biopsy, blood was taken and levels of CatD, alanine aminotransferase (ALT), and cytokeratin-18 (CK-18) were measured in plasma. RESULTS: Plasma CatD levels were significantly lower in subjects with liver inflammation compared with steatotic subjects. Furthermore, we found that CatD levels were gradually reduced and corresponded with increasing severity of liver inflammation, steatosis, hepatocellular ballooning, and NAFLD activity score. CatD levels correlated with pediatric NAFLD disease progression better than ALT and CK-18. In particular, CatD showed a high diagnostic accuracy (area under receiver operating characteristic curve (ROC-AUC): 0.94) for the differentiation between steatosis and hepatic inflammation, and reached almost the maximum accuracy (ROC-AUC: 0.998) upon the addition of CK-18. CONCLUSIONS: Plasma CatD holds a high diagnostic value to distinguish pediatric patients with hepatic inflammation from children with steatosis.
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2011-02-11 Impact factor: 17.425
Authors: Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Veerle Bieghs; Fons Verheyen; Patrick J van Gorp; Tim Hendrikx; Kristiaan Wouters; Dieter Lütjohann; Marion J J Gijbels; Maria Febbraio; Christoph J Binder; Marten H Hofker; Ronit Shiri-Sverdlov Journal: PLoS One Date: 2012-03-28 Impact factor: 3.240
Authors: Sofie M A Walenbergh; Tom Houben; Sander S Rensen; Veerle Bieghs; Tim Hendrikx; Patrick J van Gorp; Yvonne Oligschlaeger; Mike L J Jeurissen; Marion J J Gijbels; Wim A Buurman; Anita C E Vreugdenhil; Jan Willem M Greve; Jogchum Plat; Marten H Hofker; Satish Kalhan; Jussi Pihlajamäki; Patrick Lindsey; Ger H Koek; Ronit Shiri-Sverdlov Journal: Sci Rep Date: 2016-12-06 Impact factor: 4.379
Authors: Magnus Dencker; Tina Tanha; Magnus K Karlsson; Per Wollmer; Lars B Andersen; Ola Thorsson Journal: PLoS One Date: 2017-11-17 Impact factor: 3.240
Authors: Anna Di Sessa; Grazia Cirillo; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice Journal: Pediatric Health Med Ther Date: 2019-08-23